STOCK TITAN

NovoCure Ltd - NVCR STOCK NEWS

Welcome to our dedicated news page for NovoCure (Ticker: NVCR), a resource for investors and traders seeking the latest updates and insights on NovoCure.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NovoCure's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NovoCure's position in the market.

Rhea-AI Summary
Novocure's phase 3 clinical trial for ovarian cancer did not meet its primary endpoint of overall survival (OS), but a potential survival benefit was observed in patients who received only one prior line of therapy. Further exploration is needed for this subgroup. TTFields therapy was well-tolerated with no added systemic toxicities. The company remains committed to researching and exploring innovative approaches for platinum-resistant ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.5%
Tags
clinical trial
-
Rhea-AI Summary
Novocure (NASDAQ: NVCR) executives to participate in two investor conferences, the Wells Fargo Healthcare Conference on September 7 and the Morgan Stanley Global Healthcare Conference on September 13.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
conferences
-
Rhea-AI Summary
Novocure (NVCR) reports $126 million in net revenues for Q2 2023, with 3,571 active patients on therapy as of June 30, 2023. The Phase 3 LUNAR trial in non-small cell lung cancer met primary and key secondary survival endpoints, with plans for 3 more phase 3 trials by end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.89%
Tags
earnings
Rhea-AI Summary
Novocure (NASDAQ: NVCR) announces positive results from pre-specified interim analysis of PANOVA-3 clinical trial, recommending continuation to final analysis. The trial evaluates the safety and efficacy of TTFields therapy for unresectable, locally advanced pancreatic cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
clinical trial
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.3%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
clinical trial
NovoCure Ltd

Nasdaq:NVCR

NVCR Rankings

NVCR Stock Data

1.57B
95.92M
1.67%
85.89%
5.27%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Jersey
No 4 Grenville Street

About NVCR

we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.